Continuum Advisory’s Definium Therapeutics DFTX Stock Holding History

Continuum Advisory’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-239	Closed	-$1.4K	–	1130
2025 Q1	$1.4K	Hold	239	–	–	﹤0.01%	1446
2024 Q4	$1.66K	Hold	239	–	–	﹤0.01%	1477
2024 Q3	$2K	Buy	239 +219	+1,095%	+$1.52K	﹤0.01%	1427
2024 Q2	$144	Hold	20	–	–	﹤0.01%	1678
2024 Q1	$182	Buy	+20	New	+$114	﹤0.01%	1670

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Continuum Advisory's DFTX Position: Q2 2025 in Review

Continuum Advisory sold out of Definium Therapeutics (DFTX) in Q2 2025, closing a stake of 239 shares — an estimated $1.4K sold.

Continuum Advisory first reported a position in DFTX in Q1 2024 and held it in 5 quarters. The position peaked at $2K in Q3 2024. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

Continuum Advisory reported no remaining Definium Therapeutics position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 239 Definium Therapeutics shares in Q2 2025, an estimated $1.4K.
Continuum Advisory first reported a position in Definium Therapeutics in Q1 2024 and held it in 5 quarters.
Continuum Advisory's Definium Therapeutics position peaked at $2K in Q3 2024.
181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.